Hologic (NASDAQ:HOLX) Issues Q1 Earnings Guidance

Hologic (NASDAQ:HOLX) issued an update on its first quarter earnings guidance on Monday morning. The company provided EPS guidance of $1.00-1.03 for the period, compared to the consensus EPS estimate of $1.03. The company issued revenue guidance of $1.025-1.035 billion, compared to the consensus revenue estimate of $1.04 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. boosted their target price on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday. UBS Group boosted their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday. Mizuho cut their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday. Leerink Partners lowered their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 27th. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $89.25.

Hologic Trading Up 1.3 %

Shares of HOLX stock traded up $1.03 during mid-day trading on Wednesday, hitting $79.83. 693,500 shares of the company’s stock were exchanged, compared to its average volume of 1,587,046. The stock has a market cap of $18.54 billion, a price-to-earnings ratio of 26.80, a PEG ratio of 2.98 and a beta of 0.98. The stock has a 50-day simple moving average of $81.05 and a two-hundred day simple moving average of $78.11. Hologic has a fifty-two week low of $66.93 and a fifty-two week high of $84.67. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. The company had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.89 EPS. Equities analysts expect that Hologic will post 4.09 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.